Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 06, 2025
|% Change Since: 48.01%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
Xeris Biopharma's earnings call highlighted significant revenue growth and positive developments in their product portfolio, particularly with Recorlev and Gvoke. The company also achieved positive adjusted EBITDA for the first time. Despite the decline in Keveyis revenue and anticipated pressure on its reimbursement, the company is optimistic about its growth prospects for 2025.Company Guidance
In the call, Xeris Biopharma provided guidance for 2025, projecting total company revenue between $255 million and $275 million, which represents more than 30% year-over-year growth at the midpoint. They reported adjusted EBITDA turned positive in the fourth quarter of 2024 and will remain positive going forward. The company anticipates primary revenue growth drivers to be Recorlev and Gvoke, with Keveyis expected to maintain its performance. They also noted a 24% increase in total revenue for 2024, reaching over $203 million, with Recorlev experiencing 118% growth, generating $64 million. Gvoke revenue increased by 24% to nearly $83 million, and Keveyis revenue was approximately $50 million despite a 13% decline. Additionally, the company is excited about their pipeline advancement, particularly the XP-8121 product for hypothyroidism, which is moving towards Phase 3.Record-Breaking Revenue and Growth
Xeris Biopharma exceeded their full year guidance with total revenue of over $203 million, growing 24% versus last year. Product revenue growth was 28% for the full year 2024 versus 2023.
Exceptional Performance of Recorlev
Recorlev generated more than $64 million in total revenue in 2024, representing an impressive 118% growth compared to 2023. In Q4 alone, Recorlev net revenue was $22.6 million, a 131% increase compared to the same period in 2023.
Positive Adjusted EBITDA
For the first time, Xeris reported adjusted EBITDA, which turned positive in the fourth quarter and is expected to remain positive going forward.
Strong Performance of Gvoke
Gvoke achieved nearly $83 million in revenue for the full year, an increase of 24% versus 2023 with prescriptions totaling 265,000.
Guidance for 2025
Xeris is guiding total company revenue between $255 million and $275 million in 2025, representing more than 30% year-over-year growth at the midpoint.
---
XERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 06, 2025 | $3.77 | $4.13 | +9.55% |
| Nov 08, 2024 | $3.36 | $3.47 | +3.27% |
| Aug 08, 2024 | $2.13 | $2.23 | +4.69% |
| May 09, 2024 | $1.85 | $1.88 | +1.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xeris Pharmaceuticals (XERS) report earnings?
Xeris Pharmaceuticals (XERS) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Xeris Pharmaceuticals (XERS) earnings time?
Xeris Pharmaceuticals (XERS) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XERS EPS forecast?
XERS EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---